Recursion Pharmaceuticals Achieves Clinical Milestone in FAP Trial, Extends Cash Runway to 2028
Event summary
- Recursion's REC-4881 showed 75% of evaluable patients with reduced polyp burden in Phase 2 FAP trial.
- Achieved fifth milestone with Sanofi, totaling $134 million in payments to date.
- Cash position of $754 million extends runway into early 2028 without additional financing.
- Roche and Genentech accepted two neuroscience Phenomaps, receiving $60 million in milestone payments.
- 2025 R&D expenses were $475.3 million, down from $314.4 million in 2024 due to operational efficiencies.
The big picture
Recursion's clinical validation of its AI-driven drug discovery platform marks a strategic shift from proving AI's role in drug discovery to demonstrating its ability to generate durable patient outcomes. The company's extended cash runway and operational efficiencies reflect disciplined capital allocation amid a competitive biotech landscape. The growing portfolio of partnered programs with Sanofi, Roche, and Genentech underscores the industry's increasing reliance on AI-native platforms to tackle complex biological targets.
What we're watching
- Clinical Validation
- How REC-4881's durable reduction in polyp burden will impact FDA engagement and registration pathway discussions in 1H26.
- Partnership Dynamics
- Whether Sanofi's advancing programs will trigger additional near-term milestones in the next 12-18 months.
- Execution Risk
- The pace at which Recursion can translate biological insights from Roche and Genentech Phenomaps into early-stage programs.
Related topics